Genentech Plans September Debut of New $240M Rx Fill/Finish Plant in Oregon

The plant is designed to accommodate Genentech's needs and those of its partner-turned-acquirer, Roche. The facility's packaging lines are now being validated, which is required for Genentech to begin making and shipping drugs.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.